What is the role of interleukin 33 and ST2 receptor in myasthenia gravis?

Myasthenia gravis (MG) is a disease with autoimmune etiology. The main pathomechanism is related to the production of antibodies against nicotinic acetylcholine receptor (AChR) located in the postsynaptic membrane. The present study is set to compare the serum level of interleukin-33 (IL-33)/recepto...

Full description

Saved in:
Bibliographic Details
Published in:Journal of neuroimmunology 2018-02, Vol.315, p.50-57
Main Authors: Rozmilowska, Izabela Monika, Adamczyk-Sowa, Monika Helena
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Myasthenia gravis (MG) is a disease with autoimmune etiology. The main pathomechanism is related to the production of antibodies against nicotinic acetylcholine receptor (AChR) located in the postsynaptic membrane. The present study is set to compare the serum level of interleukin-33 (IL-33)/receptor ST2 in patients with myasthenia gravis and controls; and to study the relation with the severity of disease. Our observations confirm that a significant increase in serum concentrations of IL-33 and ST2 was observed in MG patients compared to healthy individuals. This relation is not precisely known yet, which requires more studies. [Display omitted] •Analysing some diseases with autoimmune grounds provide proofs for biological impact of interleukin IL-33 and its receptor.•Patients with MG occurs a significant increase of IL-33 concentration and its receptor ST2 in blood serum.•The changes in level of Il-33 and ST2 rec. in blood of patients with MG suggest their possible part in the pathogenesis.
ISSN:0165-5728
1872-8421
DOI:10.1016/j.jneuroim.2017.12.015